Role of chemotherapy and novel biological agents in the treatment of elderly patients with colorectal cancer

Abstract

Patients older than 65 years are the fastest growing segment of the cancer population. It is estimated that within 20 years over 75% of cases and 85% of deaths from colorectal cancer (CRC) will be in this setting. Concerns about cancer treatment in the elderly relate to comorbidities, which increase proportionally with age, physiological changes associated with aging which may influence drug metabolism and toxicity, and diminishing life expectancy, which particularly impacts decisions surrounding the benefits of adjuvant therapies. Over the last 10 years, significant improvements in the treatment of advanced CRC with combination therapy have been made. The randomized trials which have defined these improvements did not exclude elderly patients. However, the median age of patients in these trials has generally been approximately 60 years. Thus, it appears that some degree of selection is involved with younger and presumably fitter patients being the subjects in most of the pivotal trials. The availability of new molecularly targeted agents and newly improved existing agents has expanded the range of treatment options available. This variety gives greater flexibility in dealing with different subsets of patients, such as the elderly. However, some fit elderly patients seem to tolerate combination therapy reasonably well, while studies on unfit elderly subjects are needed.

Clinical study of the relationship between inflammatory bowel diseases and colorectal neoplasms

“…Patients with newly diagnosed CRC had a median age of 70 years abroad. 8 The eight patients with a carcinogenic trend in our series had an average age of 52.88±5.43 years (a range of 32-75 years) and thus were much younger than that what has been reported in the foreign literature. But our patients had a younger age of onset of the disease, and the average course was 13±3.78 years.…”